Rony Sfeir

Dr. Rony Sfeir

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
RSRony Sfeir
Rony Sfeir
ABArnaud Bonnard
Arnaud Bonnard
NKNaziha Khen-Dunlop
Naziha Khen-Dunlop
FAFrederic Auber
Frederic Auber
TGThomas Gelas
Thomas Gelas
FGfréderic gottrand
fréderic gottrand

1 July 2010 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
LSLydia Serhal
Lydia Serhal
FGfréderic gottrand
fréderic gottrand
RSRony Sfeir
Rony Sfeir
DGDominique Guimber
Dominique Guimber
PDPatrick Devos
Patrick Devos
LMLaurent Michaud
Laurent Michaud

29 June 2012 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
CLCéline Legrand
Céline Legrand
LMLaurent Michaud
Laurent Michaud
JSJulia Salleron
Julia Salleron
DNDorothée Neut
Dorothée Neut
RSRony Sfeir
Rony Sfeir
FGfréderic gottrand
fréderic gottrand
Objective The aim of this study was to evaluate the outcome of patients with oesophageal atresia type III (EA), focusing on the presence of late sequelae and quality of life. Methods This was a retrospective case ascertainment followed by clinical assessment of patients. The study parameters included the patients' demographic characteristics, associated abnormalities, presence of gastro-oesophageal reflux disease (GERD) and digestive or respiratory symptoms, results of a clinical examination to evaluate nutritional status, spirometry results and quality of life assessed using the PedsQL 4.0 questionnaire. Results Of 81 patients with EA type III treated in our institution over a 10-year period, 57 (mean age 13.3 (SE 2.8) years) participated in the study. 39% of the patients underwent fundoplication and 46% presented with anastomotic stenosis requiring dilation. 75% of patients had normal nutritional status (16% were obese, 9% were undernourished). Only 19% of participants had no digestive symptoms; 61% had dysphagia and 35% had symptoms of GERD at the last follow-up. The main respiratory symptoms were chronic cough (19%) and dyspnoea on exertion (37%). Only 37% of patients had no respiratory symptoms. Spirometry showed that 50% of patients had proximal obstruction and/or pulmonary distension, and 11% had restriction syndrome. Their quality of life was good but was lower than in healthy controls (80 vs 84, p<0.05) and lower in patients born prematurely, with symptoms of GERD and with a barky cough. Conclusion The high frequency of late sequelae in EA type III justifies regular and multidisciplinary follow-up through to adulthood.

11 December 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ASAnne Schneider
Anne Schneider
SBSébastien Blanc
Sébastien Blanc
ABArnaud Bonnard
Arnaud Bonnard
NKNaziha Khen-Dunlop
Naziha Khen-Dunlop
FAFrédéric Auber
Frédéric Auber
LMLaurent Michaud
Laurent Michaud
The aim of the present national prospective population-based study was to assess the early morbidity of esophageal atresia (EA). All 38 multidisciplinary French centers that care for patients with EA returned a specific questionnaire about the 1-year outcome for each patient. This information was centralized, checked, and entered into a database. From the total population of 307 EA patients born in 2008 and 2009, data about the 1-year outcome were obtained from 301 (98%) patients, of whom 4% were lost to follow-up and 5% died. Medical complications occurred in 34% of the patients: anastomotic leaks (8%), recurrent tracheoesophageal fistula (4%), and anastomotic stenosis (22%); all of the latter group needed dilation (median, 2 dilations/patient). A new hospitalization was required for 59% of patients (2.5 hospitalizations/patient) for digestive (52%) or respiratory (48%) reasons. Twelve percent of patients required antireflux surgery at a median age of 164 days (range, 33–398 days), and 1% underwent an aortopexy for severe tracheomalacia. The weight/age Z-score was −0.8 (range, −5.5 to 3.7 months) at 12 months. Fifteen percent of patients were undernourished at 12 months of age, whereas 37% presented with respiratory symptoms and 15% had dysphagia at the last follow-up. Significant independent factors associated with medical complications were anastomotic esophageal tension (p = .0009) and presence of a gastrostomy (p = .0002); exclusive oral feeding at discharge was associated with a decreased risk of complications (p = .007). Digestive and respiratory morbidities remain frequent during the first year of life and are associated with difficult anastomosis and lack of full oral feeding.

16 May 2013 in Diseases of the Esophagus
Verified
Journal Article
Closed access
RSRony Sfeir
Rony Sfeir
LML. Michaud
L. Michaud
JSJ. Salleron
J. Salleron
FGfréderic gottrand
fréderic gottrand

1 December 2008 in Pediatrics
Verified
Journal Article
Closed access
SWStephanie Willot
Stephanie Willot
SUStephanie Uhlen
Stephanie Uhlen
LMLaurent Michaud
Laurent Michaud
GBGilbert Briand
Gilbert Briand
MBMichel Bonnevalle
Michel Bonnevalle
FGfréderic gottrand
fréderic gottrand
OBJECTIVES. Although ursodeoxycholic acid has been used to treat various cholestatic liver diseases in children, few data are available about its efficacy in biliary atresia. The aim of this study was to assess the effect of ursodeoxycholic acid treatment on liver function in children who underwent successful surgery for biliary atresia. PATIENTS AND METHODS. We prospectively studied 16 children with biliary atresia who underwent successful portoenterostomies (postoperative conjugated bilirubin concentration: <34 μmol/L) and were treated with ursodeoxycholic acid for at least 18 months after surgery. Ursodeoxycholic acid treatment was then discontinued. Clinical and biological assessment was performed at the time of discontinuation of ursodeoxycholic acid treatment (T0), at follow-up (T1) and, if the clinical or biological status worsened, after resumption of ursodeoxycholic acid treatment (T2). RESULTS. Ursodeoxycholic acid treatment was resumed in 13 cases. In 1 patient, jaundice recurred after ursodeoxycholic acid therapy was discontinued but abated after resumption of treatment. In 13 children, liver function worsened significantly when ursodeoxycholic acid was discontinued. T1 versus T0 concentrations expressed as multiples of the upper limit of the normal range (in parentheses) were as follows: alanine aminotransferase, 3.0 ×N (0.8–7.0) vs 1.5 ×N (0.5–5.4); γ glutamyl transpeptidase, 8.0 ×N (1.8–30.2) vs 4.2 ×N (0.5–27.4); and aspartate aminotransferase, 1.7 ×N (0.7–6.0) vs 1.3 ×N (0.6–3.4). When ursodeoxycholic acid treatment was resumed, liver function had improved in all patients by T2. Concentrations of endogenous bile acids tended to be elevated at T1 (not significant) and were significantly decreased at T2. CONCLUSION. Our study demonstrates the beneficial effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia.